Physician profile
Vikisha Hazariwala
NPI 1497312441
$1,117.07
in general payments reported to CMS, 2019-2025
11 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Pediatric Ophthalmology and Strabismus Specialist provider received nationally (typical 2025 total: $118).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $249 · 2023: $441 · 2024: $217 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $507.37 | 2022-2025 | Clareon, Tryptyr |
| Amgen INC. | $202.12 | 2024-2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $109.09 | 2023 | Tecnis Iol, Tecnis Iol, Tecnis Simplicity |
| Sight Sciences, INC. | $92.83 | 2022-2024 | Omni Surgical System |
| Glaukos Corporation | $63.67 | 2024-2025 | Photrexa, Kxl System (Not Refurbished) |
| Bausch & Lomb Americas INC. | $46.61 | 2022-2025 | Vyzulta |
| Dompe US, INC. | $25.20 | 2024 | Oxervate |
| Abbvie INC. | $24.00 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.03 | 2022 | |
| Oyster Point Pharma, INC. | $15.58 | 2025 | Ryzumvi, Tyrvaya |
| Harrow Eye, LLC | $13.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikisha Hazariwala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.